Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

GSK Signs Up For Isis Technology

by Lisa M. Jarvis
April 5, 2010 | A version of this story appeared in Volume 88, Issue 14

In a deal worth up to $1.5 billion, Isis Pharmaceuticals will deploy its antisense drug discovery platform to develop new targets for rare disorders, including infectious diseases, for GlaxoSmithKline. Isis scores $35 million up front and could get an average of $20 million in milestone payments for every drug that reaches Phase II trials. At that proof-of-concept stage, GSK has the right to license the compounds and handle their late-stage development. According to Isis, if GSK opts in on all six drugs covered by the pact, Isis will rake in $1.5 billion, along with double-digit royalties on sales of any drugs that reach the market. Isis' antisense platform uses second-generation oligonucleotides to prevent messenger RNA from reaching its target.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.